Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reuse Supplemental Validation Data Submission NSE Rate At 25%

This article was originally published in The Gray Sheet

Executive Summary

CDRH is preparing to contact reprocessors of single-use devices that were deemed "not substantially equivalent" based on its review of supplemental validation (SV) data

You may also be interested in...



New Reprocessor Guidance Will Refine Advice On Standards, Packaging

FDA will update guidance on premarket submissions of validation data for reprocessed single-use devices in a document to be released within the next several months

New Reprocessor Guidance Will Refine Advice On Standards, Packaging

FDA will update guidance on premarket submissions of validation data for reprocessed single-use devices in a document to be released within the next several months

Validating Reuse: Single-Use Device Oversight Taxes FDA Workload

AdvaMed is pressing FDA to review validation data for all reprocessed single-use devices

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel